1/16
06:32 pm
nuvb
Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib [Yahoo! Finance]
Low
Report
Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib [Yahoo! Finance]
1/16
11:26 am
nuvb
A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal [Yahoo! Finance]
Low
Report
A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal [Yahoo! Finance]
1/12
09:29 am
nuvb
Nuvation Bio (NYSE:NUVB) had its price target lowered by analysts at HC Wainwright from $18.00 to $17.00. They now have a "buy" rating on the stock.
High
Report
Nuvation Bio (NYSE:NUVB) had its price target lowered by analysts at HC Wainwright from $18.00 to $17.00. They now have a "buy" rating on the stock.
1/12
08:55 am
nuvb
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
High
Report
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/12
08:44 am
nuvb
Nuvation Bio says preliminary Q4 and FY25 IBTROZI net product revenue was $15.7M and $24.7M [Seeking Alpha]
High
Report
Nuvation Bio says preliminary Q4 and FY25 IBTROZI net product revenue was $15.7M and $24.7M [Seeking Alpha]
1/12
08:00 am
nuvb
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
High
Report
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
1/12
07:30 am
nuvb
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
High
Report
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
1/9
06:10 am
nuvb
Nuvation Bio (NYSE:NUVB) was upgraded by analysts at UBS Group AG to a "hold" rating.
Medium
Report
Nuvation Bio (NYSE:NUVB) was upgraded by analysts at UBS Group AG to a "hold" rating.
1/7
02:01 am
nuvb
Nuvation Bio (NYSE:NUVB) is now covered by analysts at UBS Group AG. They set a "neutral" rating on the stock.
Medium
Report
Nuvation Bio (NYSE:NUVB) is now covered by analysts at UBS Group AG. They set a "neutral" rating on the stock.
1/6
04:39 pm
nuvb
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/6
04:05 pm
nuvb
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/4
03:28 am
nuvb
ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy [Seeking Alpha]
Low
Report
ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy [Seeking Alpha]
12/17
08:40 am
nuvb
Has Nuvation Bio's 234% Surge in 2025 Already Reflected Its Growth Potential? [Yahoo! Finance]
Low
Report
Has Nuvation Bio's 234% Surge in 2025 Already Reflected Its Growth Potential? [Yahoo! Finance]
12/16
09:14 pm
nuvb
Nuvation Bio (NUVB): Reassessing Valuation After a 78% Monthly Surge in the Share Price [Yahoo! Finance]
Low
Report
Nuvation Bio (NUVB): Reassessing Valuation After a 78% Monthly Surge in the Share Price [Yahoo! Finance]
12/11
08:07 am
nuvb
Nuvation Bio (NYSE:NUVB) had its price target raised by analysts at HC Wainwright from $10.00 to $18.00. They now have a "buy" rating on the stock.
Medium
Report
Nuvation Bio (NYSE:NUVB) had its price target raised by analysts at HC Wainwright from $10.00 to $18.00. They now have a "buy" rating on the stock.
12/6
10:40 pm
nuvb
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
Low
Report
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
12/4
01:11 pm
nuvb
Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result [Yahoo! Finance]
Low
Report
Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result [Yahoo! Finance]
12/4
12:12 am
nuvb
Lenz Therapeutics: A Close Look [Seeking Alpha]
Low
Report
Lenz Therapeutics: A Close Look [Seeking Alpha]
12/3
11:58 am
nuvb
Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Medium
Report
Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript [Seeking Alpha]
12/3
08:00 am
nuvb
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
High
Report
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
12/1
07:20 am
nuvb
Nuvation Bio (NYSE:NUVB) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Neutral
Report
Nuvation Bio (NYSE:NUVB) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/29
04:40 am
nuvb
Nuvation Bio: A Strong Company Now Fairly Priced [Seeking Alpha]
Low
Report
Nuvation Bio: A Strong Company Now Fairly Priced [Seeking Alpha]
11/28
06:44 am
nuvb
Nuvation Bio (NUVB) Halts NUV-1511 and Highlights Safusidenib Data Is Strategic Focus Shifting? [Yahoo! Finance]
Low
Report
Nuvation Bio (NUVB) Halts NUV-1511 and Highlights Safusidenib Data Is Strategic Focus Shifting? [Yahoo! Finance]
11/27
10:35 pm
nuvb
Nuvation Bio (NUVB): Exploring Valuation After a 52% One-Month Rally [Yahoo! Finance]
Low
Report
Nuvation Bio (NUVB): Exploring Valuation After a 52% One-Month Rally [Yahoo! Finance]
11/26
04:05 pm
nuvb
Nuvation Bio to Participate in Upcoming Investor Conferences
Low
Report
Nuvation Bio to Participate in Upcoming Investor Conferences